Access Bio, Inc. is launching its CareStart COVID-19 MDx RT-PCR molecular test to detect the SARS CoV-2 virus following receipt of an emergency use authorization (EUA) from the US Food and Drug Administration, the company announced on 23 July.
CareStart COVID-19 MDx RT-PCR detects nucleic acid sequences unique to SARS-CoV-2 that have been extracted, isolated, and purified from nasopharyngeal or oropharyngeal swab specimens. Specifically, it uses real-time reverse transcription-polymerase...